Immune-modulation medicine represents one of the most exciting areas of pharmaceutical research and development today. The concepts of educating the immune system to target specific antigens and boosting its ability to fight disease have broad application. Themis is leveraging its unique technology platform to build a proprietary pipeline that includes both vaccines and novel anti-cancer approaches. The opportunity is based in Themis’ proven ability to target the innate immune system, rapidly develop product candidates and manufacture them. Themis will support the development of vaccines for indications with serious outbreak potential through non-dilutive partnerships like recent agreement with the Coalition for Epidemic Preparedness Innovations (CEPI). In parallel, Themis will advance its own proprietary pipeline of products to treat large market infectious diseases and cancer.